Indazole Kinase Inhibitor for Imatinib-Resistant GIST
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current kinase inhibitors, such as Imatinib, are ineffective against the Imatinib-resistant cKIT-T670I mutation in gastrointestinal stromal tumors (GIST), necessitating a novel inhibitor that can selectively target and inhibit this mutation without affecting wild-type cKIT.
Innovation Solution
A selective kinase inhibitor with a novel compound structure, specifically designed to inhibit cKIT-T670I, FLT3, PDGFRα, PDGFRβ, and VEGFR2, comprising a compound of formula (I) or its pharmaceutically acceptable salts, solvates, esters, acids, metabolites, or prodrugs, which selectively targets and inhibits the mutant cKIT-T670I while minimizing impact on wild-type cKIT.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multi-target kinase inhibitors (e.g., Imatinib, Sunitinib, Regorafenib, Ponatinib) are used to treat GIST, then broad kinase inhibition activity is achieved, but selectivity against mutant cKIT-T670I is lost and off-target effects increase
Solution Approach 1:
The patent applies local quality by designing a inhibitor with specific structural features (amino group at position 2, hydroxyl group at position 6 of the pyridine ring) that create localized interactions with the mutant cKIT-T670I binding pocket. This localized structural optimization enables selective inhibition of the mutant form while maintaining minimal activity against wild-type cKIT and other kinases, resolving the contradiction between broad adaptability and specific reliability.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as the position and type of substituents on the pyridine core, the nature of the linker group, and the terminal functional groups. These parameter optimizations were guided by structure-activity relationship (SAR) studies that identified specific parameter combinations (e.g., 2-amino-6-hydroxypyridine with specific linkers) that maximize mutant selectivity while minimizing off-target effects, thus achieving both versatility and reliability.
2Reliability
If type II kinase inhibitors are used to target cKIT-T670I mutation, then inhibitory activity against the mutation is achieved, but the ability to overcome drug resistance is limited
Solution Approach 1:
The patent applies dynamics by designing a flexible molecule that can adapt its conformation to bind effectively to the mutant cKIT-T670I active site. The linker region between the pyridine core and terminal groups provides rotational freedom, allowing the inhibitor to dynamically adjust its shape to fit the mutated binding pocket, thereby maintaining high inhibitory activity and overcoming resistance mechanisms that rigid type II inhibitors cannot address.
Solution Approach 2:
The patent uses composite material principles by combining multiple functional moieties into a single hybrid molecule: a 2-amino-6-hydroxypyridine pharmacophore for mutant recognition, a flexible linker for conformational adaptability, and terminal functional groups for additional binding interactions. This composite structure integrates the advantages of different molecular components to achieve both potent mutant inhibition and broad resistance-overcoming capability.
3Ease of manufacture
If conventional kinase inhibitors are used, then surgical treatment alternatives are provided, but effectiveness against Imatinib-resistant tumors is insufficient
Solution Approach 1:
The patent applies the intermediary principle by introducing a novel chemical compound as a mediator between the unmet clinical need and effective treatment. This small molecule inhibitor acts as an intermediary that specifically targets the molecular defect (cKIT-T670I mutation) responsible for Imatinib resistance, translating genetic understanding into therapeutic effect and providing an effective non-surgical treatment option for previously untreatable resistant tumors.
Data Source
AI summary
Described herein is a kinase inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug of the compound. Further described herein is a pharmaceutical composition containing the kinase inhibitor compound, as well as methods of using the compound to inhibit cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFRα, PDGFRβ, and/or VEGFR2 kinase activity in cells or a subject, and methods for preventing or treating disorders related to cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFRα, PDGFRβ, and/or VEGFR2 activity in a subject.